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Objective. To identify the oral carriage of Candida spp in patients infected by human immunodeficiency virus (HIV) and the
possible correlation with clinical characteristics.
Study Design. Mucosal swab samples collected from 246 patients who were infected by HIV, did not have oral candidiasis,
and were being treated with highly active antiretroviral therapy were analyzed. Yeast colonies that developed were identified
by using the VITEK 2 automated system.
Results. Candida yeasts were present in 41.87% of the samples, and Candida albicanswas the most prevalent (32.52%). Other
identified Candida species were C tropicalis (4.88%), C parapsilosis (2.85%), C dubliniensis (0.81%), and C famata (0.81%).
Conclusions. There was low rate of oral Candida carriage in patients infected by HIV who were on highly active antiretroviral
therapy. A greater prevalence of C albicans than non-albicans Candida species was found at the species level. Prior
candidiasis predicted the oral carriage of C albicans; however, it did not influence the carriage of non-albicans species. This is
the first report of oral carriage of C famata in patients with HIV infection. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;
120:29-33)Oral candidiasis is the most common fungal infection in
immunocompromised patients, infecting approximately
90% of patients with acquired immunodeﬁciency syn-
drome (AIDS),1 and the episodes are often recurrent.2,3
Candida albicans is the leading species of yeast that
causes candidiasis, and its treatment is based on anti-
fungal drugs. Because of the high prevalence of
candidiasis in patients infected by human immunode-
ﬁciency virus (HIV), there is an increase in the use of
antifungal drugs to treat these infections. A signiﬁcant
increase in drug resistance has been observed, as a
result of the increased prevalence of non-albicans
Candida species, which reportedly do not respond to
conventional antifungal therapy.4-6 Because candidiasis
is caused by Candida spp that normally colonize the
mucosal surfaces, the risk of the development of non-
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AIDS causes deterioration of the immune system and
predisposes affected individuals to a number of
complications, such as the development of cancer,7
renal and cardiovascular diseases, lipodystrophy,
changes in bone metabolism and vitamin D
deﬁciency, and a variety of infectious diseases, such
as pneumonia and tuberculosis.8 Patients with HIV
exhibit several oral manifestations, many of which
reﬂect immunodeﬁciency. A very common ﬁnding in
patients with HIV is oropharyngeal candidiasis.9
Candida spp is a familyof saprophyticmicroorganisms,
which, depending on predisposing factors, may become
pathogenic and cause candidiasis.3 There are several types
of oral manifestations of candidiasis, including
pseudomembranous, erythematous, hyperplastic, and
mucocutaneous candidiasis and angular cheilitis.6,10,11
The treatment of oral candidiasis is widely discussed
in the literature as a result of increasing drug resistanceStatement of Clinical Relevance
Patients infected by human immunodeﬁciency virus
and have undergone highly active antiretroviral
therapy show low rates of carriage of oral Candida,
with predominance of the Candida albicans species.
However, they may present with novel non-albicans
species, such as the C famata identiﬁed in this
Brazilian cohort.
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with HIV.10,12 A small number of antifungal agents are
used to treat candidiasis, including polyenes, such as
nystatin and amphotericin B; azoles, including ketoco-
nazole, itraconazole, and ﬂuconazole; and newer azoles,
such as voriconazole and posaconazole.3,13 The devel-
opment of azole antifungals was a great advance in the
treatment of fungal infections, but their widespread use
in the treatment of immunocompromised patients has
increased the number of strains resistant to these anti-
fungal agents, mainly the non-albicans Candida
species.14
Since the spread of the AIDS epidemic in the early
1980s, the treatment for HIV infection has evolved
considerably with the development of antiretroviral
therapies. Highly active antiretroviral therapy
(HAART) is now the gold standard for treating the
disease and has increased the survival rates and
improved the quality of life of patients with HIV.15
HAART has reduced the occurrence of opportunistic
infections, although candidiasis continues to affect
many of these patients (30.1% to 37%).16,17 These pa-
tients still have a lower prevalence (30.1%) compared
with those patients who have not undergone HAART
(69.1%).16
Given the large number of patients with HIV and the
strong association with the development of candidiasis,
as well as the increase in the morbidity and mortality
among patients with HIV, this study aimed to identify
the different species of Candida found in the oral cavity
of patients on HAART who have not yet developed
AIDS. Furthermore, we tested the relationship of the
demographic and clinical characteristics, such as
gender, previous episodes of candidiasis, and CD4þ
cell count, which could act as predisposing factors for
the oral carriage of Candida spp. The identiﬁcation of
Candida species colonizing the oral cavity and the
possible predisposing factors may indicate a shift in the
species composition and the trend of species currently
found in the oral cavity of patients with HIV.
MATERIALS AND METHODS
Samples for mycology were collected by using oral
mucosal swabs from 246 patients with HIV (conﬁrmed
by enzyme-linked immunosorbent assay and Western
blot analysis) treated at a specialized center for treat-
ment of infectious and parasitic diseases (URE-DIPE)
in Belém, Brazil. This unit provides care to patients
with HIV from across the state of Pará, northern Brazil.
All patients were informed of the study objectives, and
informed consent forms were signed. This study was
approved by the Ethics Committee in Research of the
Institute of Health Sciences, Federal University of Pará
(ICS-UFPA), protocol number 120/09 CEP-ICS/UFPA.
All patients who agreed to take part in this studyunderwent oral clinical examination by 1 examiner
(experienced in special care dentistry), who assessed
the patients for signs and symptoms of oral candidiasis,
according to the following criteria: burning sensation,
buccal pain, dysphagia, erythema with or without
soreness, white patches, redness, ﬁssuring, and soreness
at the angle of the mouth. Adult patients over 18 years
of age who were on HAART and did not show clinical
signs or symptoms of oral candidiasis or the active
phase of AIDS were included in this study.Isolation and identification of Candida species
Samples were collected by using sterile swabs from the
buccal mucosa of the oral cavity, plated in duplicate in
15  160 mm test tubes, and sealed with hydrophobic
buffer containing 5 mL of sabouraud dextrose agar with
chloramphenicol (Merck KGaA, Darmstadt, Germany).
All samples were processed in the Laboratory of
Bacteriology and Mycology of the Instituto Evandro
Chagas IEC/SVS/MS.
Yeast colonies that developed a moistened appear-
ance and white-yellowish color were kept in the
mycology unit at room temperature for 15 days.
Candida species were identiﬁed by using the automated
Vitek 2 system and Vitek 2 ID-YST card for identifying
clinically important yeasts and yeast-like organisms
(BioMérieux, Grenoble, France).Statistical analysis
Data were analyzed with the use of BioEstat 5.0 soft-
ware (BioEstat Software, Belém, PA). Multiple logistic
regression was used to analyze correlation between
three different groups (Candida spp, Candida albicans,
and non-albicans Candida) and the following predis-
posing factors: previous candidiasis, CD4þ count
<200, and gender.RESULTS
Of the 246 patients with HIV included in this study,
46.34% were female and 53.66% male. Patients’ ages
ranged between 18 and 66 years, and the average age
was 39 years. Of the strains that were grown, 103 were
of the genus Candida; the majority of them were C
albicans (77.67%). Among the non-albicans species in
the oral cavity, C tropicalis (52.17%), C parapsilosis
(30.43%), C dubliniensis (8.7%), and C famata (8.7%)
were identiﬁed (Table I).
We tested whether gender, CD4þ cell count, and
prior occurrence of candidiasis were related to the
presence or absence of Candida in the oral cavity.
Multiple logistic regression analysis was performed to
assess this association. Patients who had a previous
candidiasis infection showed twofold higher odds for
Table I. Identiﬁcation of Candida species found in oral
cavity of 246 patients infected by human immunodeﬁ-
ciency virus (HIV) in treatment with highly active an-
tiretroviral therapy (HAART)
Description Species No. %
General sample Not found 143 58.13
Candida albicans 80 32.52
C tropicalis 12 4.88
C parapsilosis 7 2.85
C dubliniensis 2 0.81
C famata 2 0.81
Total - 246 100
Candida spp C albicans 80 77.67
Candida non-albicans 23 22.33
Total - 103 100
Candida non-albicans C tropicalis 12 52.17
C parapsilosis 7 30.43
C dubliniensis 2 8.70
C famata 2 8.70
Total - 23 100
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signiﬁcant differences were not found between carriage
of non-albicans species of Candida and any of the
variables studied (Table II).DISCUSSION
Oral carriage of Candida species is relatively common
in individuals with HIV, affecting approximately 62%
to 67% of them.18-20 Our results showed that 41.87% of
the samples collected from the oral cavities of patients
with HIV, grew Candida colonies. Of these, approxi-
mately 77.67% were C albicans, which was more
frequent than the reported prevalence in the literature
(32% to 62%).10,18,19 Our results suggest a low preva-
lence of oral cavity colonization by Candida sppTable II. Multiple logistic regression for oral carriage of Ca
virus (HIV) in treatment with highly active antiretroviral the
Predisposing factors RC (b) SE
Previous candidiasis 0.6558 0.2790
CD4þ <200 0.4257 0.3311
Male 0.1396 0.2641
Predisposing factors
Previous candidiasis 0.6992 0.2992
CD4þ <200 0.4791 0.3526
Male 0.2049 0.2861
Predisposing factors
Previous candidiasis 0.5034 0.4730
CD4þ <200 0.2867 0.5633
Male 0.0297 0.4566
RC, regression coefﬁcient; SE, standard error; OR, odds ratio; CI, conﬁdenc(41.87%) as well as by non-albicans Candida species
(9.35%).
The advent of HAART has allowed for the sup-
pression of viral replication to very low levels and a
partial recovery of CD4þ cells in patients with HIV,
which has consequently reduced opportunistic in-
fections.20,21 The low prevalence of oral carriage of
Candida spp found in this study may reﬂect the fact that
the Brazilian government currently guarantees free and
universal access to HAART for all patients with HIV.22
Despite the relatively low level of asymptomatic oral
carriage of Candida in our study (41.87%), the
prevalence is, nevertheless, greater than the average
(34.4%) reported in a healthy population not infected
by HIV.23 This study showed that patients who had
previous candidiasis have a high probability of
asymptomatic oral carriage of Candida spp and C
albicans.
We analyzed factors that could inﬂuence the oral
carriage of Candida in patients with HIV. The most
important factor was a prior infection by Candida. This
was the unique statistically signiﬁcant predisposing
factor present in this study, although a low count of
CD4þ cells was an important contributor to increase
the probability of oral Candida carriage. A CD4þ cell
count less than 200 cells/mL is considered a predis-
posing factor for candidiasis.24 However, our results
indicate that only a low CD4þ cell count in patients
on HAART is not associated to high risk of oral
Candida carriage.18,20
We hypothesized that patients who had had previous
episodes of candidiasis would be more prone to oral
carriage of non-albicans Candida due to the selection
mechanisms and resistance of the yeast species. How-
ever, we found that patients who had previous candi-
diasis were more prone to oral carriage of C albicans
than the non-albicans Candida species. Furthermore,ndida in patients infected by human immunodeﬁciency
rapy (HAART)
Candida spp
OR CI 95% P
1.9267 1.12-3.33 .0187
1.5307 0.80-2.93 .1985
0.8697 0.52-1.46 .5972
Candida albicans
2.0120 1.12-3.62 .0195
1.6146 0.81-3.22 .1742
0.8147 0.47-1.43 .4738
non-albicans Candida
1.6544 0.65-4.18 .2872
1.3321 0.44-4.02 .6107
1.0302 0.42-2.52 .9481
e interval.
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not inﬂuenced by prior infection or any other variable
studied. Only three patients who presented with oral
carriage of non-albicans Candida had had previous
episodes of candidiasis and remembered their treat-
ment. Two of them who had used nystatin, showed oral
carriage of C tropicalis and C parapsilosis, and the
third, who reported the use of ﬂuconazole, demon-
strated oral carriage of C parapsilosis.
The results of this study demonstrate that oral car-
riage of non-albicans Candida species in patients with
HIV is lower than that reported in the literature. These
data may reﬂect 2 factors. The ﬁrst is free and universal
access to HAART offered by the Brazilian government,
which ensures a gold standard treatment to the whole
population. The second factor is the lack of uniformity
in the treatment of candidiasis.
Despite the prevalence of oral carriage of C albicans
seen in this study, 23 cultures (9.35%) grew non-albi-
cans Candida species. Among these, C tropicalis was
the most common (12 cases), which was followed by C
parapsilosis, C dubliniensis, and C famata. Coloniza-
tion by species of C tropicalis, C parapsilosis, and C
dubliniensis is a relatively common ﬁnding, with
prevalence varying by study location.10,25,26 Unex-
pectedly, we found two cases of C famata, which is a
rare human pathogen that is commonly found in natural
sources or in processed food products.27 These two
cases were found in men aged 31 and 38 years who
had never had a previous episode of candidiasis.
C famata belongs to the group of ﬂavinogenic yeasts
that can oversynthesize riboﬂavin when they are iron
deﬁcient. Some strains of C famata belong to the most
ﬂavinogenic organisms, and these have long been used for
the industrial production of riboﬂavin.27 In a multicentric
study on the epidemiology of candidiasis in Latin
America, 672 cases of candidiasis were studied, and
only a single case of C famata was found.25 Another
study with 300 Turkish children found only 2 cases of
oral C famata in a speciﬁc 6-8-year-old age group.28 We
found a rare colonization of C famata, the ﬁrst to be
reported in patients infected by HIV according to the
literature. Studies have shown that C famata is less
sensitive to ﬂuconazole and itraconazole and has
intermediate susceptibility to amphotericin B and that
posaconazole and voriconazole are the most effective
inhibitors of C famata strains.29
We found that the main species of Candida in the
oral cavity of asymptomatic patients with HIV (C
albicans, C tropicalis, C parapsilosis, and C dublin-
iensis) accounted for 98.06% of all yeasts grown. Ac-
cording to the literature, these species are associated
with low resistance to the main antifungal drugs (ke-
toconazole, itraconazole, and amphotericin B),19,20,25,29
and this suggests that empirical therapy with any ofthese 3 drugs in this population should prove to be
efﬁcient and effective treatment.
Therefore, we conclude that there was a low carriage
of Candida in the oral cavity of patients with HIV and a
higher prevalence of C albicans than non-albicans
species of Candida in comparison with similar studies.
These ﬁndings may be the result of the free and uni-
versal access to HAART for AIDS treatment in Brazil.
The previous occurrence of candidiasis is a predispos-
ing factor for the oral carriage of C albicans but not the
carriage of non-albicans Candida species. This sug-
gests that previous candidiasis does not shift the species
composition of the oral cavity to more aggressive and
drug-resistant non-albicans Candida species in the
studied population. According to the consulted litera-
ture, this was the ﬁrst report of carriage of C famata in
the oral cavity of patients with HIV.
The author Andre Luis Ribeiro Ribeiro is grateful to the
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